Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DASATINIB vs DATOPOTAMAB DERUXTECAN-DLNK: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DASATINIB vs DATOPOTAMAB DERUXTECAN-DLNK: Safety Overview

Metric DASATINIB DATOPOTAMAB DERUXTECAN-DLNK
Total FAERS Reports 30,019 165
Deaths Reported 2,681 36
Death Rate 8.9% 21.8%
Hospitalizations 6,437 33
Average Patient Age 56.4 yrs 61.4 yrs
% Female Patients 51.9% 89.2%
FDA Approval Date Apr 22, 2025 N/A
Manufacturer Zydus Pharmaceuticals USA Inc. N/A
Route ORAL N/A
Marketing Status Prescription Prescription